Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

6(66.7%)

N/A

3(33.3%)

9Total

Phase 1(6)

N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03461419Not ApplicableSuspended

Use of Stromal Vascular Fraction in Multiple Sclerosis

Role: lead

NCT03514537Not ApplicableSuspended

Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) In Frailty-Aging Processes

Role: lead

NCT02946658Phase 1Suspended

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders

Role: lead

NCT02849470Phase 1Withdrawn

AGA Biocellular Stem/Stromal Hair Regenerative Study

Role: lead

NCT02952131Phase 1Suspended

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease

Role: lead

NCT04238143Not ApplicableRecruiting

Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis

Role: lead

NCT03909750Phase 1Suspended

Use of Autologous Stem/Stromal Cells In Chronic Lung Disorders: Obstructive (COPD) & Restrictive (RLD)

Role: lead

NCT02987855Phase 1Withdrawn

Adipose Stem/Stromal Cells in RSD, CRPS, Fibromyalgia

Role: lead

NCT02939859Phase 1Withdrawn

Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions

Role: lead

All 9 trials loaded